KURA
Kura Oncology, Inc. NASDAQ Listed Sep 16, 2015$11.73
+0.09%
vs $11.72
Mkt Cap $1.0B
52w Low $7.36
66.8% of range
52w High $13.90
50d MA $11.18
200d MA $9.81
P/E (TTM)
—
EV/EBITDA
—
P/B
5.9x
Debt/Equity
0.1x
ROE
-160.0%
P/FCF
-14.5x
RSI (14)
36.80
ATR (14)
$0.48
Beta
0.24
50d MA
$11.18
200d MA
$9.81
Avg Volume
2.2M
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
12730 High Bluff Drive · San Diego, CA 92130 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | AMC | -0.88 | -0.77 | +12.2% | 9.94 | +6.7% | +1.5% | +7.6% | +3.9% | +9.3% | +1.6% | — |
| May 12, 2026 | AMC | -0.88 | -0.83 | +5.7% | 9.68 | -7.3% | -2.1% | +2.7% | -5.3% | -0.2% | -2.6% | — |
| Mar 5, 2026 | AMC | -0.72 | -0.92 | -27.8% | 8.51 | -2.7% | +5.3% | +4.8% | -1.4% | -0.4% | -4.1% | — |
| Nov 4, 2025 | AMC | -0.57 | -0.85 | -49.1% | 9.96 | +0.1% | -0.2% | +2.2% | -3.0% | +4.7% | +3.6% | — |
| Aug 7, 2025 | AMC | 0.15 | -0.75 | -600.0% | 5.96 | -4.4% | -7.0% | +0.0% | +11.9% | +4.7% | +1.7% | — |
| May 1, 2025 | AMC | -0.51 | -0.66 | -29.4% | 6.49 | -4.0% | -0.3% | +3.9% | -13.8% | -2.4% | +6.2% | — |
| Feb 26, 2025 | AMC | -0.65 | -0.22 | +66.2% | 7.77 | +2.6% | -1.5% | +0.8% | -6.0% | +1.1% | +0.5% | — |
| Nov 7, 2024 | AMC | -0.64 | -0.63 | +1.6% | 17.77 | -5.6% | -0.5% | -0.7% | +5.8% | -4.4% | -7.1% | — |
| Aug 8, 2024 | AMC | -0.63 | -0.59 | +6.3% | 19.12 | +0.4% | -0.8% | +0.1% | +0.3% | +0.1% | +2.2% | — |
| May 2, 2024 | AMC | -0.56 | -0.59 | -5.4% | 20.59 | -0.2% | +0.2% | +1.8% | +0.3% | -2.5% | +1.1% | — |
| Feb 27, 2024 | AMC | -0.56 | -0.55 | +1.8% | 21.76 | -0.0% | -1.7% | -1.4% | +2.4% | -1.3% | -1.3% | — |
| Nov 2, 2023 | AMC | -0.56 | -0.50 | +10.7% | 8.42 | +4.0% | +7.0% | -0.2% | +3.1% | -2.4% | -5.0% | — |
| Aug 3, 2023 | AMC | -0.57 | -0.53 | +7.0% | 10.54 | -0.5% | +4.4% | -5.2% | -0.3% | +3.5% | +2.6% | — |
| May 10, 2023 | AMC | -0.54 | -0.50 | +7.4% | 11.45 | -0.5% | +8.3% | -1.3% | +3.4% | -1.1% | -0.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24 | Mizuho | Maintains | Outperform → Outperform | — | $8.32 | $8.23 | -1.1% | -3.0% | +5.9% | -2.2% | -7.4% | -0.1% |
| Mar 13 | UBS | Maintains | Buy → Buy | — | $8.84 | $8.91 | +0.8% | -2.1% | +0.9% | -1.7% | -2.2% | +0.5% |
| Mar 6 | Wedbush | Maintains | Outperform → Outperform | — | $8.51 | $8.28 | -2.7% | +5.3% | +4.8% | -1.4% | -0.4% | -4.1% |
| Jan 13 | Leerink Partners | Maintains | Outperform → Outperform | — | $9.17 | $9.02 | -1.6% | +0.4% | +1.6% | -4.8% | -5.1% | +1.7% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.17 | $9.02 | -1.6% | +0.4% | +1.6% | -4.8% | -5.1% | +1.7% |
| Nov 24 | Barclays | Maintains | Overweight → Overweight | — | $11.17 | $11.38 | +1.9% | +5.0% | -1.1% | +3.4% | +1.3% | -5.8% |
| Nov 14 | Wedbush | Maintains | Outperform → Outperform | — | $10.68 | $10.75 | +0.7% | +5.0% | -3.2% | +2.1% | +2.2% | -3.0% |
| Nov 14 | UBS | Maintains | Buy → Buy | — | $10.68 | $10.75 | +0.7% | +5.0% | -3.2% | +2.1% | +2.2% | -3.0% |
| Oct 20 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $9.84 | $10.24 | +4.1% | +1.5% | -4.1% | -3.1% | -1.9% | +6.6% |
| Oct 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.84 | $10.24 | +4.1% | +1.5% | -4.1% | -3.1% | -1.9% | +6.6% |
| Sep 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.97 | $8.89 | -0.9% | -1.3% | +4.0% | -0.7% | +4.7% | +2.4% |
| Aug 11 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $5.54 | $5.55 | +0.2% | +0.0% | +11.9% | +4.7% | +1.7% | +11.2% |
| Jun 26 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.80 | $5.80 | +0.0% | -1.2% | -1.0% | +1.8% | -2.9% | +3.8% |
| Jun 20 | Wedbush | Maintains | Outperform → Outperform | — | $6.06 | $6.11 | +0.8% | -3.5% | +0.3% | +1.9% | -3.0% | -1.2% |
| Jun 4 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $6.42 | $6.46 | +0.6% | +0.5% | +1.9% | +2.4% | +0.0% | +1.2% |
| May 19 | Mizuho | Maintains | Outperform → Outperform | — | $6.02 | $5.96 | -1.0% | +3.7% | +2.2% | -2.8% | +0.6% | -9.6% |
| May 2 | Barclays | Maintains | Overweight → Overweight | — | $6.49 | $6.23 | -4.0% | -0.3% | +3.9% | -13.8% | -2.4% | +6.2% |
| Apr 29 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $6.51 | $6.51 | +0.0% | +0.2% | +0.6% | -1.1% | -0.3% | +3.9% |
| Apr 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.43 | $6.46 | +0.5% | +1.2% | +0.2% | +0.6% | -1.1% | -0.3% |
| Mar 6 | UBS | Maintains | Buy → Buy | — | $7.37 | $7.19 | -2.4% | +4.5% | -2.2% | -3.9% | +1.2% | +5.2% |
| Feb 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.77 | $7.97 | +2.6% | -1.5% | +0.8% | -6.0% | +1.1% | +0.5% |
| Feb 6 | Wedbush | Maintains | Outperform → Outperform | — | $9.05 | $8.15 | -9.9% | -2.5% | -1.9% | +1.6% | -5.1% | +0.1% |
| Feb 6 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $9.05 | $8.15 | -9.9% | -2.5% | -1.9% | +1.6% | -5.1% | +0.1% |
| Feb 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.05 | $8.15 | -9.9% | -2.5% | -1.9% | +1.6% | -5.1% | +0.1% |
| Jan 8 | Scotiabank | Maintains | Sector Perform → Sector Perform | — | $8.17 | $8.07 | -1.2% | -4.8% | -5.9% | -1.1% | +0.3% | -0.3% |
| Dec 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $10.67 | $10.76 | +0.8% | -1.3% | -2.3% | -0.9% | -5.0% | -0.6% |
| Nov 22 | BofA Securities | Maintains | Buy → Buy | — | $10.06 | $10.27 | +2.1% | +7.4% | +1.5% | -1.9% | +3.9% | -1.2% |
| Nov 21 | Jefferies | Maintains | Buy → Buy | — | $15.91 | $11.80 | -25.8% | -36.8% | +7.4% | +1.5% | -1.9% | +3.9% |
| Nov 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.91 | $11.80 | -25.8% | -36.8% | +7.4% | +1.5% | -1.9% | +3.9% |
| Nov 19 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $16.04 | $15.92 | -0.7% | -0.5% | -0.3% | -36.8% | +7.4% | +1.5% |
| Nov 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.92 | $15.99 | +0.4% | +0.8% | -0.5% | -0.3% | -36.8% | +7.4% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.57 | $18.63 | +0.3% | -4.4% | -7.1% | -3.5% | +0.8% | -0.5% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.52 | $18.04 | +3.0% | +1.8% | -0.4% | -0.5% | -0.7% | +5.8% |
| Oct 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.02 | $17.85 | +4.9% | +4.5% | -1.5% | +1.3% | -2.1% | -2.2% |
| Oct 14 | Stifel | Downgrade | Buy → Hold | — | $18.58 | $17.98 | -3.2% | -2.8% | +0.8% | +0.3% | -1.0% | -0.5% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.97 | $19.09 | +0.6% | +0.1% | +0.3% | +0.1% | +2.2% | -1.0% |
| Aug 12 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $18.97 | $19.09 | +0.6% | +0.1% | +0.3% | +0.1% | +2.2% | -1.0% |
| Aug 9 | Wedbush | Maintains | Outperform → Outperform | — | $19.12 | $19.20 | +0.4% | -0.8% | +0.1% | +0.3% | +0.1% | +2.2% |
| Aug 9 | Stifel | Maintains | Buy → Buy | — | $19.12 | $19.20 | +0.4% | -0.8% | +0.1% | +0.3% | +0.1% | +2.2% |
| Jun 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.94 | $21.15 | +1.0% | +0.7% | -2.8% | +0.5% | -0.5% | +0.4% |
| Jun 18 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $20.69 | $20.73 | +0.2% | -4.4% | +2.8% | +3.1% | +0.7% | -2.8% |
| May 16 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $21.87 | $21.78 | -0.4% | +5.1% | -3.5% | +0.3% | -0.6% | +2.0% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.61 | $20.92 | +1.5% | +1.5% | +4.6% | +5.1% | -3.5% | +0.3% |
| May 6 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $20.63 | $20.77 | +0.7% | +1.8% | +0.3% | -2.5% | +1.1% | -0.3% |
| May 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.59 | $20.55 | -0.2% | +0.2% | +1.8% | +0.3% | -2.5% | +1.1% |
| May 3 | Wedbush | Maintains | Outperform → Outperform | — | $20.59 | $20.55 | -0.2% | +0.2% | +1.8% | +0.3% | -2.5% | +1.1% |
| Apr 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.53 | $18.33 | +4.6% | +3.8% | +3.0% | +0.1% | +1.3% | +3.4% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.04 | $21.31 | +1.3% | +7.9% | -1.9% | +5.7% | -3.0% | -2.2% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.76 | $21.75 | -0.0% | -1.7% | -1.4% | +2.4% | -1.3% | -1.3% |
| Feb 28 | Wedbush | Maintains | Outperform → Outperform | — | $21.76 | $21.75 | -0.0% | -1.7% | -1.4% | +2.4% | -1.3% | -1.3% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Aug 24, 2026 | WILSON TROY EDWARD | President and CEO | Buy | 100,000 | $12.39 | $1.2M | 479,194 | +9.60% | -0.08% |
| Aug 21, 2026 | Powl Brian T. | Chief Commercial Officer | Sell | 4,345 | $11.89 | $52K | 169,269 | +9.60% | -0.08% |
| Aug 17, 2026 | WILSON TROY EDWARD | President and CEO | Buy | 100,000 | $11.12 | $1.1M | 379,194 | +9.31% | +4.29% |
| Jun 18, 2026 | Leoni Mollie | Chief Medical Officer | Sell | 84,929 | $9.82 | $834K | 182,345 | +0.19% | +0.64% |
| May 19, 2026 | Powl Brian T. | Chief Commercial Officer | Sell | 339 | $9.21 | $3K | 183,614 | +7.64% | -2.64% |
| May 19, 2026 | FORD KATHLEEN | Chief Operating Officer | Sell | 2,257 | $9.08 | $20K | 153,560 | +7.64% | -2.64% |
| May 18, 2026 | Bair Teresa Brophy | Chief Legal Officer | Sell | 2,256 | $9.38 | $21K | 226,931 | +7.64% | -2.64% |
8-K
Kura Oncology, Inc. -- 8-K Filing
Sep 9
8-K
Kura Oncology, Inc. -- 8-K Filing
Sep 8
8-K
Kura Oncology, Inc. -- 8-K Filing
Kura Oncology reported 2025 financial results and provided a corporate update, likely including cash position and pipeline progress that will inform investor assessment of the company's runway and development trajectory.
Mar 5
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Blackrock, Inc. | 10,509,233 | $115M | New | Jun 2026 |
| 2 | Vanguard Capital Management Llc | 3,916,164 | $43M | Added | Jun 2026 |
| 3 | Aqr Capital Management Llc | 3,126,727 | $34M | Added | Jun 2026 |
| 4 | Morgan Stanley | 2,779,656 | $29M | Reduced | Dec 2025 |
| 5 | Deep Track Capital, Lp | 1,978,565 | $22M | New | Jun 2026 |
| 6 | Renaissance Technologies Llc | 1,663,765 | $18M | Added | Jun 2026 |
| 7 | Vanguard Portfolio Management Llc | 1,329,941 | $15M | Added | Jun 2026 |
| 8 | Qube Research & Technologies Ltd | 1,636,733 | $13M | Added | Mar 2026 |
| 9 | Nan Fung Trinity (Hk) Ltd | 1,174,880 | $13M | Added | Jun 2026 |
| 10 | Connor, Clark & Lunn Investment Management Ltd. | 996,114 | $11M | Added | Jun 2026 |
| 11 | Bank Of America Corp /de/ | 1,230,131 | $10M | Added | Mar 2026 |
| 12 | Ubs Group Ag | 1,040,233 | $8M | Reduced | Mar 2026 |
| 13 | Millennium Management Llc | 711,332 | $8M | Reduced | Jun 2026 |
| 14 | Citadel Advisors Llc | 656,210 | $7M | Reduced | Jun 2026 |
| 15 | Rhenman & Partners Asset Management Ab | 591,500 | $6M | Added | Jun 2026 |
| 16 | Hennion & Walsh Asset Management, Inc. | 568,845 | $6M | New | Jun 2026 |
| 17 | Northern Trust Corp | 756,273 | $6M | Added | Mar 2026 |
| 18 | Jupiter Asset Management Ltd | 509,886 | $6M | New | Jun 2026 |
| 19 | Jane Street Group, Llc | 477,145 | $5M | Added | Dec 2025 |
| 20 | Man Group Plc | 475,027 | $4M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.04B
Enterprise Value
$370.9M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.06x
P/B
5.91x
P/S
13.48x
P/FCF
-14.55x
EV/EBITDA
—
Shares Out
87.7M
Financials (TTM)
Revenue
$77.2M
Net Income
-$296.8M
EBITDA
-$292.4M
Free Cash Flow
-$70.7M
Op Cash Flow
-$64.1M
EPS Basic
$-3.18
EPS Diluted
$-3.37
EPS Forward
$-3.57
Gross Margin
94.7%
Op Margin
-411.9%
Net Margin
-384.3%
Balance Sheet
Total Assets
$738.4M
Total Liab.
$564.2M
Total Equity
$174.1M
Cash
$667.2M
LT Debt
$9.7M
Book Value/Sh
$1.99
Debt/Equity
0.12x
Current Ratio
6.06
Quick Ratio
6.05
Returns & Growth
ROE
-160.0%
ROA
-37.7%
ROIC
-48.8%
Rev Growth YoY
+25.2%
EPS Growth YoY
-57.4%
Price Returns
2W
-10.8%
1M
-6.4%
3M
+13.2%
6M
+39.1%
12M
+42.2%
Technicals
52W High
$13.90
52W Low
$7.36
50d MA
$11.18
200d MA
$9.81
RSI (14)
36.80
ATR (14)
$0.48
Beta
0.24
Avg Volume
2.2M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$27.33
High
$40.00
Low
$15.00
Median
$25.50
Data updated apr 25, 2026 6:11pm
· Source: financialmodelingprep.com